MultiValent Biotherapies, Inc., 2026-02-27
An SEC Form D private-offering notice from Los Altos, CA, a $4,375 filer-stated offering target in Biotech. Filed 2026-02-27. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Develops targeted drug conjugate therapies for cancer, including a dual targeting prostate cancer treatment licensed from Coherent Biopharma.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Newwork Software Inc., 2026-03-02, $1.2M, Palo Alto, CA
- Haku Bio, Inc., 2026-03-02, Arlington, MA
- MultiValent Biotherapies, Inc., 2026-03-02, Los Altos, CA
- Ventaris Surgical, Inc., 2026-03-02, $30.7M, San Carlos, CA
- MeltPlan, Inc., 2026-02-27, $17.5M, Berkeley, CA
- Conexeu Sciences Inc., 2026-02-27, $1.1M, Reno, NV
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.